EICHORCondition: Advanced Solid Tumor · Sponsor: Third Arc Bio
Interested? Contact the study team ↓
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of ARC101 in patients with advanced cancer.
This description comes directly from the study's public registry record.
VP Clinical Operations · 267-589-9444 · clinicaltrials@thirdarcbio.com
There is no obligation to join — the study team can answer your questions about taking part.
Always discuss trial participation with your own doctor first.
Inclusion Criteria: * Locally advanced or metastatic solid tumor ovarian, testicular or other Claudin 6+ cancers * Measurable or evaluable disease, per RECIST v1.1 * Eastern Cooperative Oncology Group (ECOG) performance status 0-1 * Adequate organ function Exclusion Criteria: * Active CNS involvement * Malignancy diagnosis other than the disease under study within 2 years prior to the first dose of study drug. * Presence of uncontrolled ascites * Toxicity related to prior anticancer therapy that has not returned to Grade ≤1 or baseline levels * Clinically significant pulmonary compromise * Active autoimmune disease within 12 months prior to first dose of study drug. * Female participant who is pregnant, breastfeeding, or plans to become pregnant or male participant who plans to father a child either while enrolled or within 90 days after the final administration of study drug.
Reproduced word-for-word from the public registry record — the study team can answer questions about it.
| Massachusetts General Hospital | Boston, Massachusetts, United States | Recruiting |
| START Midwest | Grand Rapids, Michigan, United States | Recruiting |
| START San Antonio, LLC. | San Antonio, Texas, United States | Recruiting |
| Sunshine Coast University Private Hospital | Birtinya, Queensland, Australia | Recruiting |
| Cancer Research SA | Adelaide, South Australia, Australia | Recruiting |
| Cabrini Health Research | Malvern, Victoria, Australia | Recruiting |
| BC Cancer Research Centre | Vancouver, British Columbia, Canada | Recruiting |
| The Princess Margaret Cancer Centre | Toronto, Ontario, Canada | Recruiting |
| McGill University Health Centre | Montreal, Quebec, Canada | Recruiting |
| Rambam Medical Center | Haifa, Israel | Recruiting |
| Sheba Medical Center | Ramat Gan, Israel | Recruiting |
| Sourasky Medical Center | Tel Aviv, Israel | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06672185